Showing session: reset
Clinical Trials of Targeted Agents in Solid Tumors
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
Fabrice Andre
Institut Gustave Roussy, Villejuif, France
- Free
- slides video
- audio + slides
- All slides included
Discussant
Roman K Thomas
Max Planck Inst. for Neurological Research, Cologne, Germany
- Free
- audio + slides
- Some slides withheld
Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur
Novartis, Emeryville, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
David B Solit
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Free
- Unknown permission
for presentation
A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME)
José Baselga
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
- Free
- Coming soon
- All slides included
Discussant
Rachel Schiff
Baylor College of Medicine, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial
Jeffrey R Infante
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States
- Permission not
granted for presentation
Discussant
Jeffrey A Engelman
Massachusetts General Hospital, Charlestown, MA, United States